Metis TechBio Co Ltd has completed an initial public offering in Hong Kong, raising more than HK$2.1 billion to support the development of its AI-driven drug delivery technologies and clinical programmes.

• Financial Performance: Revenue increased from 1.5 million yuan in 2024 to 105 million yuan in 2025, while net losses narrowed from 499 million yuan to 392 million yuan.
• Capital Allocation: Around 50% of the IPO proceeds will fund expansion of the company’s AI infrastructure and nanomaterial platform, with approximately 20% allocated to ongoing and planned clinical trials.
• Technology Platform: The company’s NanoForge platform combines AI models, molecular simulation and high-throughput screening to design nanomaterial drug carriers and has generated more than 10 pipeline programmes.

This summary is based on an article published by China Daily.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.